Skip to content

Study · Randomized controlled trial · n = 805 · 2013

7 results

Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3',5'-monophosphate.

Castro J, Harrington AM, Hughes PA, Martin CM, Ge P, Shea CM, Jin H, Jacobson S, Hannig G, Mann E, Cohen MB, MacDougall JE and 7 more

Show all authors

Lavins BJ, Kurtz CB, Silos-Santiago I, Johnston JM, Currie MG, Blackshaw LA, Brierley SM

Gastroenterology16 Aug 2013Cited by 236 (Europe PMC)

PMID23958540 (opens in a new tab)DOI10.1053/j.gastro.2013.08.017 (opens in a new tab)PepBankPUB-23958540
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study7

4 results from studies that gave the peptide. 1 result from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In IBS-C patients, at least 30% abdominal pain reduction occurred in 70% with linaclotide versus 50% with placebo over 26 weeks.

    In plain wordsIn IBS-C patients, linaclotide increased the proportion with reduced abdominal pain versus placebo.

    Peptide
    Linaclotide
    Outcome
    IncreaseAt least 30% abdominal pain reduction
    Study

    n = 805

    Comparator
    Placebo
    Outcome group
    Pain · Gastrointestinal
    Studied dose
    290 μg once daily · oral · 26 weeksAs given in this study (human).

    Measurements

    Patients with at least 30% reduction in abdominal pain
    70%
    linaclotide 290 μg once daily for 26 weeks
    Patients with at least 30% reduction in abdominal pain
    50%
    placebo for 26 weeks

    Source sentences

    Summary
    During 26 weeks of linaclotide administration, a significantly greater percentage of patients (70%) had at least a 30% reduction in abdominal pain compared with patients given placebo (50%).
    1 context sentence
    Summary · context
    We performed a post-hoc analysis of data from a phase III, double-blind, parallel-group study in which 805 patients with IBS-C were randomly assigned to groups given an oral placebo or 290 μg linaclotide once daily for 26 weeks.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In mice, linaclotide inhibited colonic nociceptors more effectively during chronic visceral hypersensitivity than in healthy conditions.

    In plain wordsIn mice, linaclotide inhibited pain-sensing nerves more effectively during chronic gut hypersensitivity than in healthy conditions.

    Peptide
    Linaclotide
    Outcome
    DecreaseColonic nociceptor activity
    Study

    mousen: not reported in source

    Healthy and chronic visceral hypersensitivity mice
    Outcome group
    Pain · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In mice, linaclotide inhibited colonic nociceptors with greater efficacy during chronic visceral hypersensitivity.
    1 context sentence
    Summary · context
    We determined the effects of linaclotide on colonic sensory afferents in healthy mice and those with chronic visceral hypersensitivity.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In mice, intra-colonic linaclotide reduced spinal signaling caused by noxious colorectal distention.

    In plain wordsIn mice, linaclotide reduced pain signals to the spinal cord after colorectal distention.

    Peptide
    Linaclotide
    Outcome
    DecreaseSpinal signaling after colorectal distention
    Study

    mousen: not reported in source

    Outcome group
    Pain · Gastrointestinal
    Studied dose
    Dose not stated · intra-colonicAs given in this study (mouse).

    Source sentences

    Summary
    Intra-colonic administration of linaclotide reduced signaling of noxious colorectal distention to the spinal cord.
    1 context sentence
    Summary · context
    We assessed pain transmission by measuring activation of dorsal horn neurons in the spinal cord in response to noxious colorectal distention.
  4. 04LabIn vitro (cells)Mechanism

    In human intestinal cells, linaclotide administration triggered cGMP release.

    In plain wordsIn cells, linaclotide triggered cGMP release.

    Peptide
    Linaclotide
    Outcome
    IncreasecGMP release
    Study

    humann: not reported in source

    Human intestinal cell lines
    Outcome group
    Receptor activity and mechanism · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The downstream effector of GC-C, cGMP, was released after administration of linaclotide
    1 context sentence
    Summary · context
    We used human intestinal cell lines to measure release of cyclic guanosine-3',5'-monophosphate (cGMP) by linaclotide.

Studies that did not test the peptide alone3

In this study, Linaclotide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Linaclotide.

  1. 05AnimalNot a test of Linaclotide aloneAnimal study (in vivo)Mechanism

    In Gucy2c knockout mice, linaclotide lost its inhibitory effects on nociceptors.

    In plain wordsIn mice without Gucy2c, linaclotide lost its effects on pain-sensing nerves.

    Peptide
    Linaclotide
    Outcome
    No significant changeNociceptor inhibition without GC-C
    Study

    mousen: not reported in source

    Gucy2c knockout mice
    Outcome group
    Pain · Gastrointestinal

    Source sentences

    Summary
    The effects of linaclotide were lost in Gucy2c(-/-) mice and prevented by inhibiting cGMP transporters or removing the mucosa.

    In this study, Linaclotide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Linaclotide.

  2. 06LabNot a test of Linaclotide aloneEx vivo tissueMechanism

    In mouse colonic preparations, cGMP transporter inhibition prevented linaclotide effects on nociceptors.

    In plain wordsIn lab tests, inhibition of cGMP transporters prevented linaclotide effects on mouse pain-sensing nerves.

    Peptide
    Linaclotide
    Outcome
    No significant changeNociceptor inhibition with cGMP transporter inhibition
    Study

    mousen: not reported in source

    Colonic sensory afferents
    Outcome group
    Pain · Gastrointestinal

    Source sentences

    Summary
    The effects of linaclotide were lost in Gucy2c(-/-) mice and prevented by inhibiting cGMP transporters or removing the mucosa.
    1 context sentence
    Summary · context
    We determined the effects of linaclotide on colonic sensory afferents in healthy mice and those with chronic visceral hypersensitivity.

    In this study, Linaclotide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Linaclotide.

  3. 07LabNot a test of Linaclotide aloneEx vivo tissueMechanism

    In mouse colonic preparations, mucosa removal prevented linaclotide effects on nociceptors.

    In plain wordsIn lab tests, mucosa removal prevented linaclotide effects on mouse pain-sensing nerves.

    Peptide
    Linaclotide
    Outcome
    No significant changeNociceptor inhibition without mucosa
    Study

    mousen: not reported in source

    Colonic sensory afferents
    Outcome group
    Pain · Gastrointestinal

    Source sentences

    Summary
    The effects of linaclotide were lost in Gucy2c(-/-) mice and prevented by inhibiting cGMP transporters or removing the mucosa.
    1 context sentence
    Summary · context
    We determined the effects of linaclotide on colonic sensory afferents in healthy mice and those with chronic visceral hypersensitivity.

    In this study, Linaclotide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Linaclotide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.